Joinn Laboratories(China)Co.Ltd Valuation

Q: What is the Fair Price of 6127 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

6127 (HK$9.4) is trading above our estimate of [[fair value]] (HK$3.54)

Is 6127 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6127 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6127 (HK$9.4) is trading above our estimate of fair value (HK$3.54)

Significantly Below Fair Value: 6127 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6127?

Key metric: As 6127 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6127. This is calculated by dividing 6127's market cap by their current revenue.
What is 6127's PS Ratio?
PS Ratio	6.1x
Sales	CN¥2.12b
Market Cap	CN¥12.04b

6127 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.2x
Enterprise Value/EBITDA	28.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 6127's PS Ratio compare to its peers?

The above table shows the PS ratio for 6127 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.2x
1548 Genscript Biotech	2.8x	39.9%	HK$21.7b
2268 WuXi XDC Cayman	9.8x	26.0%	HK$29.4b
2269 WuXi Biologics (Cayman)	3.2x	10.6%	HK$59.1b
1521 Frontage Holdings	1.1x	13.6%	HK$2.1b
6127 Joinn Laboratories(China)Co.Ltd	6.1x	12.1%	HK$12.0b

Price-To-Sales vs Peers: 6127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does 6127's PS Ratio compare vs other companies in the Asian Life Sciences Industry?

8 Companies	Price / Sales	Estimated Growth	Market Cap

8 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 6127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the Asian Life Sciences industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is 6127's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6127 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.1x
Fair PS Ratio	2.6x

Price-To-Sales vs Fair Ratio: 6127 is expensive based on its Price-To-Sales Ratio (6.1x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

3SBio

HK$13.0b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

1530

HK$5.52

-4.3%

-26.2%

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

-3.3%

n/a

Innovent Biologics

HK$60.6b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$37.00

-0.5%

-15.4%